company background image

China Pharma Holdings NYSEAM:CPHI Stock Report

Last Price


Market Cap







03 Oct, 2022


Company Financials
CPHI fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health1/6

CPHI Stock Overview

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People’s Republic of China.

China Pharma Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for China Pharma Holdings
Historical stock prices
Current Share PriceUS$0.14
52 Week HighUS$0.79
52 Week LowUS$0.13
1 Month Change-24.16%
3 Month Change-36.77%
1 Year Change-72.66%
3 Year Change-44.40%
5 Year Change-19.91%
Change since IPO-99.57%

Recent News & Updates

Shareholder Returns

CPHIUS PharmaceuticalsUS Market

Return vs Industry: CPHI underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: CPHI underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is CPHI's price volatile compared to industry and market?
CPHI volatility
CPHI Average Weekly Movement9.6%
Pharmaceuticals Industry Average Movement11.2%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: CPHI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: CPHI's weekly volatility (10%) has been stable over the past year.

About the Company

1993236Zhilin Li

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People’s Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.

China Pharma Holdings Fundamentals Summary

How do China Pharma Holdings's earnings and revenue compare to its market cap?
CPHI fundamental statistics
Market CapUS$7.06m
Earnings (TTM)-US$3.73m
Revenue (TTM)US$8.09m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CPHI income statement (TTM)
Cost of RevenueUS$8.48m
Gross Profit-US$393.30k
Other ExpensesUS$3.33m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.074
Gross Margin-4.86%
Net Profit Margin-46.08%
Debt/Equity Ratio260.5%

How did CPHI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is CPHI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CPHI?

Other financial metrics that can be useful for relative valuation.

CPHI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.9x
Enterprise Value/EBITDA-833.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CPHI's PS Ratio compare to its peers?

CPHI PS Ratio vs Peers
The above table shows the PS ratio for CPHI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7.2x
SNOA Sonoma Pharmaceuticals
EMMA Emmaus Life Sciences
NBY NovaBay Pharmaceuticals
GPFT Grapefruit USA
CPHI China Pharma Holdings

Price-To-Sales vs Peers: CPHI is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (7.2x).

Price to Earnings Ratio vs Industry

How does CPHI's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: CPHI is good value based on its Price-To-Sales Ratio (0.9x) compared to the US Pharmaceuticals industry average (2.9x)

Price to Sales Ratio vs Fair Ratio

What is CPHI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CPHI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CPHI's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of CPHI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CPHI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CPHI's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is China Pharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Pharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Take a look at our analysis of CPHI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has China Pharma Holdings performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CPHI is currently unprofitable.

Growing Profit Margin: CPHI is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: CPHI is unprofitable, but has reduced losses over the past 5 years at a rate of 20.6% per year.

Accelerating Growth: Unable to compare CPHI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CPHI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).

Return on Equity

High ROE: CPHI has a negative Return on Equity (-92.56%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is China Pharma Holdings's financial position?

Financial Health Score


Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CPHI's short term assets ($6.3M) do not cover its short term liabilities ($8.4M).

Long Term Liabilities: CPHI's short term assets ($6.3M) exceed its long term liabilities ($5.5M).

Debt to Equity History and Analysis

Debt Level: CPHI's net debt to equity ratio (204.7%) is considered high.

Reducing Debt: CPHI's debt to equity ratio has increased from 24.6% to 260.5% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CPHI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CPHI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.2% each year

Discover healthy companies


What is China Pharma Holdings's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

China Pharma Holdings Dividend Yield vs Market
How does China Pharma Holdings dividend yield compare to the market?
SegmentDividend Yield
Company (China Pharma Holdings)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (China Pharma Holdings)n/a

Notable Dividend: Unable to evaluate CPHI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CPHI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CPHI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CPHI's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CPHI has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Zhilin Li (69 yo)





Ms. Zhilin Li has been the Chief Executive Officer and President of China Pharma Holdings, Inc. since October 20, 2005 and serves as its Interim Chief Financial Officer. Ms. Li is Founder of Helpson Bio-ph...

CEO Compensation Analysis

Zhilin Li's Compensation vs China Pharma Holdings Earnings
How has Zhilin Li's remuneration changed compared to China Pharma Holdings's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$242kUS$226k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$242kUS$226k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$242kUS$226k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$242kUS$226k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$242kUS$226k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016US$242kUS$226k


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015US$242kUS$226k


Compensation vs Market: Zhilin's total compensation ($USD241.60K) is below average for companies of similar size in the US market ($USD781.86K).

Compensation vs Earnings: Zhilin's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: CPHI's board of directors are seasoned and experienced ( 14.7 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CPHI?
Owner TypeNumber of SharesOwnership Percentage
Private Companies4,994,5179.9%
General Public21,590,51942.8%
Individual Insiders23,122,65145.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.8%.

Top Shareholders

Top 11 shareholders own 57.21% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Zhilin Li
13,810,000$1.9m0%no data
Heung Mei Tsui
9,312,651$1.3m0%no data
Streeterville Management LLC
4,994,517$699.2k0%no data
Renaissance Technologies LLC
318,812$44.6k-10.1%no data
Bridgeway Capital Management, LLC
195,000$27.3k0%no data
Virtu Financial LLC, Asset Management Arm
88,437$12.4k325.26%no data
Millennium Management LLC
71,152$10.0k195.69%no data
Citadel Advisors LLC
34,854$4.9k0%no data
Two Sigma Advisers, LP
23,600$3.3k-15.71%no data
UBS Asset Management
12,531$1.8k31.55%no data
First Community Trust, National Association
1,500$210.00%no data

Company Information

China Pharma Holdings, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: China Pharma Holdings, Inc.
  • Ticker: CPHI
  • Exchange: NYSEAM
  • Founded: 1993
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$7.063m
  • Shares outstanding: 50.45m
  • Website:

Number of Employees


  • China Pharma Holdings, Inc.
  • No. 17, Jinpan Road
  • Second Floor
  • Haikou
  • Hainan Province
  • 570216
  • China


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XQJDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2002

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.